RATIONALE: Human rhinovirus species C (HRV-C) is the most common cause of acute wheezing exacerbations in young children presenting to hospital, but its impact on subsequent respiratory illnesses has not been defined. OBJECTIVES: To determine whether acute wheezing exacerbations due to HRV-C are associated with increased hospital attendances due to acute respiratory illnesses (ARIs). METHODS: Clinical information and nasal samples were collected prospectively from 197 children less than 5 years of age, presenting to hospital with an acute wheezing episode. Information on hospital attendances with an ARI before and after recruitment was subsequently obtained. MEASUREMENTS AND MAIN RESULTS: HRV was the most common virus identified at recruitment (n = 135 [68.5%]). From the 120 (88.9%) samples that underwent typing, HRV-C was the most common HRV species identified, present in 81 (67.5%) samples. Children with an HRV-related wheezing illness had an increased risk of readmission with an ARI (relative risk, 3.44; 95% confidence interval, 1.17-10.17; P = 0.03) compared with those infected with any other virus. HRV-C, compared with any other virus, was associated with an increased risk of a respiratory hospital admission before (49.4% vs. 27.3%, respectively; P = 0.004) and within 12 months (34.6% vs. 17.0%; P = 0.01) of recruitment. Risk for subsequent ARI admissions was further increased in atopic subjects (relative risk, 6.82; 95% confidence interval, 2.16-21.55; P = 0.001). Admission risks were not increased for other HRV species. CONCLUSIONS: HRV-C-related wheezing illnesses were associated with an increased risk of prior and subsequent hospital respiratory admissions. These associations are consistent with HRV-C causing recurrent severe wheezing illnesses in children who are more susceptible to ARIs.
RATIONALE: Human rhinovirus species C (HRV-C) is the most common cause of acute wheezing exacerbations in young children presenting to hospital, but its impact on subsequent respiratory illnesses has not been defined. OBJECTIVES: To determine whether acute wheezing exacerbations due to HRV-C are associated with increased hospital attendances due to acute respiratory illnesses (ARIs). METHODS: Clinical information and nasal samples were collected prospectively from 197 children less than 5 years of age, presenting to hospital with an acute wheezing episode. Information on hospital attendances with an ARI before and after recruitment was subsequently obtained. MEASUREMENTS AND MAIN RESULTS: HRV was the most common virus identified at recruitment (n = 135 [68.5%]). From the 120 (88.9%) samples that underwent typing, HRV-C was the most common HRV species identified, present in 81 (67.5%) samples. Children with an HRV-related wheezing illness had an increased risk of readmission with an ARI (relative risk, 3.44; 95% confidence interval, 1.17-10.17; P = 0.03) compared with those infected with any other virus. HRV-C, compared with any other virus, was associated with an increased risk of a respiratory hospital admission before (49.4% vs. 27.3%, respectively; P = 0.004) and within 12 months (34.6% vs. 17.0%; P = 0.01) of recruitment. Risk for subsequent ARI admissions was further increased in atopic subjects (relative risk, 6.82; 95% confidence interval, 2.16-21.55; P = 0.001). Admission risks were not increased for other HRV species. CONCLUSIONS: HRV-C-related wheezing illnesses were associated with an increased risk of prior and subsequent hospital respiratory admissions. These associations are consistent with HRV-C causing recurrent severe wheezing illnesses in children who are more susceptible to ARIs.
Authors: Andrew C Martin; Ingrid A Laing; Siew-Kim Khoo; Guicheng Zhang; Kristina Rueter; Laurel Teoh; Shahir Taheri; Catherine M Hayden; Gary C Geelhoed; Jack Goldblatt; Peter N LeSouëf Journal: Am J Respir Crit Care Med Date: 2005-12-30 Impact factor: 21.405
Authors: R T Stein; D Sherrill; W J Morgan; C J Holberg; M Halonen; L M Taussig; A L Wright; F D Martinez Journal: Lancet Date: 1999-08-14 Impact factor: 79.321
Authors: Andrew C Martin; Guicheng Zhang; Kristina Rueter; Siew-Kim Khoo; Joelene Bizzintino; Catherine M Hayden; Gary C Geelhoed; Jack Goldblatt; Ingrid A Laing; Peter N Le Souëf Journal: J Asthma Date: 2008-06 Impact factor: 2.515
Authors: Wai-Ming Lee; Kris Grindle; Tressa Pappas; David J Marshall; Michael J Moser; Edward L Beaty; Peter A Shult; James R Prudent; James E Gern Journal: J Clin Microbiol Date: 2007-05-30 Impact factor: 5.948
Authors: Anne Kotaniemi-Syrjänen; Raija Vainionpää; Tiina M Reijonen; Matti Waris; Kaj Korhonen; Matti Korppi Journal: J Allergy Clin Immunol Date: 2003-01 Impact factor: 10.793
Authors: Theodor F Griggs; Yury A Bochkov; Kazuyuki Nakagome; Ann C Palmenberg; James E Gern Journal: J Virol Methods Date: 2015-02-24 Impact factor: 2.014
Authors: Kohei Hasegawa; Jonathan M Mansbach; Yury A Bochkov; James E Gern; Pedro A Piedra; Cindy S Bauer; Stephen J Teach; Susan Wu; Ashley F Sullivan; Carlos A Camargo Journal: JAMA Pediatr Date: 2019-06-01 Impact factor: 16.193
Authors: Lyndsey M Muehling; Ronald B Turner; Kenneth B Brown; Paul W Wright; James T Patrie; Sampo J Lahtinen; Markus J Lehtinen; William W Kwok; Judith A Woodfolk Journal: J Infect Dis Date: 2018-01-17 Impact factor: 5.226
Authors: Sze Man Tse; Sheryl L Rifas-Shiman; Brent A Coull; Augusto A Litonjua; Emily Oken; Diane R Gold Journal: J Allergy Clin Immunol Date: 2016-04-27 Impact factor: 10.793
Authors: Richard Hewitt; Hugo Farne; Andrew Ritchie; Emma Luke; Sebastian L Johnston; Patrick Mallia Journal: Ther Adv Respir Dis Date: 2015-11-26 Impact factor: 4.031
Authors: Kohei Hasegawa; Jonathan M Mansbach; Stephen J Teach; Erin S Fisher; Daniel Hershey; Joyce Y Koh; Sunday Clark; Pedro A Piedra; Ashley F Sullivan; Carlos A Camargo Journal: Pediatr Infect Dis J Date: 2014-08 Impact factor: 2.129